News from alkermes plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 04, 2021, 08:00 ET Alkermes to Hold Virtual Investor Day

Alkermes plc (Nasdaq: ALKS) announced today that it will hold a virtual Investor Day on Thursday, March 25, 2021, beginning at 9:00 a.m. ET (1:00 p.m....

Feb 18, 2021, 16:00 ET Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the SVB Leerink Global Healthcare...

Feb 11, 2021, 07:00 ET Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2020 and provided financial expectations for...

Feb 04, 2021, 16:00 ET Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to...

Jan 14, 2021, 07:00 ET NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine

Results from a National Institute on Drug Abuse (NIDA)-funded study evaluating the efficacy and safety of naltrexone for extended-release injectable...

Jan 06, 2021, 16:00 ET Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th...

Jan 06, 2021, 07:00 ET Alkermes Announces Updates to Executive Leadership Team

Alkermes plc (Nasdaq: ALKS), a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and...

Dec 29, 2020, 07:00 ET FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company's New Drug...

Dec 10, 2020, 07:00 ET Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment

Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and financial...

Nov 17, 2020, 07:00 ET Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review

Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...

Nov 09, 2020, 08:01 ET Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced the presentation of new data from the ARTISTRY clinical development program for ALKS 4230, Alkermes'...

Oct 29, 2020, 10:24 ET Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET

Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to...

Oct 29, 2020, 07:00 ET Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2020 and provided updated financial expectations for full-year...

Oct 22, 2020, 16:00 ET Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to...

Oct 09, 2020, 17:11 ET FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder

Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and...

Oct 09, 2020, 07:05 ET Trading in Alkermes Ordinary Shares Halted Today

Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the...

Oct 07, 2020, 10:14 ET Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Oct....

Sep 18, 2020, 06:30 ET Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress

Alkermes plc (Nasdaq: ALKS) today presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational...

Sep 14, 2020, 07:00 ET Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry...

Sep 09, 2020, 16:00 ET Alkermes to Take Part in Cantor Virtual Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Cantor...

Sep 08, 2020, 07:00 ET Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress

Alkermes plc (Nasdaq: ALKS) today announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 ...

Aug 21, 2020, 07:00 ET Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020

Alkermes plc (Nasdaq: ALKS) today announced that a joint meeting of the U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory...

Aug 19, 2020, 07:00 ET Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors

Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of...

Aug 17, 2020, 07:00 ET American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia

Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831...

Jul 29, 2020, 07:00 ET Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations

Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2020 and provided updated financial expectations for full-year ...